Welcoming a New Year of Progress and Clinical Innovation

As a new year begins, the field of dermatology is positioned for another year of growth after an eventful 2025. The past year delivered advances across medical, surgical, and aesthetic dermatology, with continued progress in biologics, small molecules, device-based therapies, and diagnostic technologies reshaping how clinicians approach patient care. Entering 2026, innovation remains a constant—driven by research, thoughtful clinical application, and the shared goal of improving outcomes across diverse disease states.

In the upcoming months, Dermatology Times will continue to spotlight emerging data, real-world evidence, and practical insights that translate research into daily practice. From novel mechanisms of action and evolving treatment algorithms to procedural refinements and technology-enabled care, 2026 promises continued evolution in how dermatologic disease is understood and managed. Equally important is the role of clinician experience in contextualizing these advances by breaking down trial data with the realities of busy practices and complex patient populations.

As part of our commitment to highlighting emerging research, we invite clinicians to submit original clinical manuscripts, case series, and practice-focused reviews for consideration. Contributions grounded in evidence, clinical relevance, and practical application are central to our mission, offering a meaningful opportunity to share insights with peers across the specialty.

Selected submissions will be featured in upcoming issues, providing authors with a platform to inform, educate, and shape ongoing clinical dialogue. For questions or to submit, email DTEditor@mmhgroup.com.

This month’s exclusive digital issue includes important insights from Karan Lal, DO, MS; Adam Friedman, MD; and Steven Daveluy, MD, on the growing role of glucagon-like peptide-1s in dermatology. Additionally, a special cover feature discusses new data showing that almost half of women with psoriasis experience intimate partner violence (IPV). Stacey Swinehart, DNP, FNP-BC, DCNP, CNL, offers guidance for clinicians on how to spot IPV among dermatologic patients.

Dermatology Times looks forward to another year of promoting collaboration, research, and clinical excellence, while amplifying the voices of dermatology clinicians who continue to advance the field.